Wells Fargo Maintains Biogen at Overweight, Raises Target to $310
Wells Fargo raised its price target on Biogen to $310 per share from $250 while maintaining its Overweight rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.